Consecutive infections and clearances of different hepatitis C virus genotypes in an injecting drug user

被引:12
作者
Aitken, Campbell Kynoch [1 ,2 ]
Tracy, Samantha Lilly [3 ]
Revill, Peter [3 ]
Bharadwaj, Mandvi [4 ]
Bowden, David Scott [3 ]
Winter, Rebecca Jane [2 ]
Hellard, Margaret Elena [2 ]
机构
[1] Macfarlane Burnet Inst Med Res & Publ Hlth, Ctr Epidemiol & Populat Hlth Res, Melbourne, Vic 3001, Australia
[2] Macfarlane Burnet Inst Med Res & Publ Hlth, Melbourne, Vic 3004, Australia
[3] Victorian Infect Dis Reference Lab, Melbourne, Vic 3051, Australia
[4] Univ Melbourne, Dept Microbiol, Parkville, Vic 3050, Australia
基金
英国医学研究理事会;
关键词
hepatitis C virus; reinfection; clearance; prevention; vaccine;
D O I
10.1016/j.jcv.2007.12.007
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: The hepatitis C virus (HCV) causes significant morbidity and mortality worldwide, and is highly prevalent among injecting drug users (IDUs). Whether initial HCV infection and clearance provides protection from reinfection has not been established, but is an important question for vaccine development. Objective: To elucidate an unusual history of HCV infection and clearance in an IDU. Study design: The subject was interviewed and gave blood samples at approximately three-month intervals; all samples were tested for anti-HCV and HCV RNA, genotyped if RNA detected, and checked for mixed genotypes; phylogenetic analysis performed on the subject's and injecting partners' core HCV sequences. Results: We observed consecutive infections with HCV genotypes 3a, 1a and 61, and intervening clearances, in a young IDU over 449 days. Genotypes 1a and 61 were probably acquired from the subject's injecting partners, who had genetically related infections. Conclusion: This case illustrates (1) the ease with which IDUs can acquire HCV, (2) that prior HCV infection does not protect against reinfection with heterologous strains, and (3) that IDUs can clear consecutive HCV infections. Our subject's history of HCV infection and clearance offers hope for vaccine development, yet demonstrates that HCV vaccines must have cross-genotypic effectiveness. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:293 / 296
页数:4
相关论文
共 20 条
[1]   Change in hepatitis C virus genotype in in ecting drug users [J].
Aitken, C ;
McCaw, R ;
Jardine, D ;
Bowden, S ;
Higgs, P ;
Nguyen, O ;
Crofts, N ;
Hellard, M .
JOURNAL OF MEDICAL VIROLOGY, 2004, 74 (04) :543-545
[2]   Indications of immune protection from hepatitis C infection [J].
Aitken, CK ;
Bowden, S ;
Hellard, M ;
Crofts, N .
JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2004, 81 (01) :58-60
[3]  
Bullock GC, 2002, CLIN CHEM, V48, P2147
[4]   Southeast Asian patients with chronic hepatitis C: The impact of novel genotypes and race on treatment outcome [J].
Dev, AT ;
McCaw, R ;
Sundararajan, V ;
Bowden, S ;
Sievert, W .
HEPATOLOGY, 2002, 36 (05) :1259-1265
[5]   Epidemiology of hepatitis C virus infection in Australia [J].
Dore, GJ ;
Law, M ;
MacDonald, M ;
Kaldor, JM .
JOURNAL OF CLINICAL VIROLOGY, 2003, 26 (02) :171-184
[6]   Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection [J].
Encke, J ;
Findeklee, J ;
Geib, J ;
Pfaff, E ;
Stremmel, W .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 142 (02) :362-369
[7]  
FELSENSTEIN J, 1993, PHYLIP PHYLOGENETIC
[8]   A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees [J].
Folgori, A ;
Capone, S ;
Ruggeri, L ;
Meola, A ;
Sporeno, E ;
Ercole, BB ;
Pezzanera, M ;
Tafi, R ;
Arcuri, M ;
Fattori, E ;
Lahm, A ;
Luzzago, A ;
Vitelli, A ;
Colloca, S ;
Cortese, R ;
Nicosia, A .
NATURE MEDICINE, 2006, 12 (02) :190-197
[9]  
Gowans EJ, 2004, J CLIN VIROL, V30, P283, DOI [10.1016/j.cv.2004.03.006, 10.1016/j.jcv.2004.03.006]
[10]   Hepatitis C virus reinfection in injection drug users [J].
Grebely, Jason ;
Conway, Brian ;
Raffa, Jesse D. ;
Lai, Calvin ;
Krajden, Mel ;
Tyndall, Mark W. .
HEPATOLOGY, 2006, 44 (05) :1139-1145